# ANVS catalysts: Annovis Bio, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/anvs/catalysts

> Annovis Bio, Inc. (ANVS) has 7 upcoming catalysts. The next is the TDP-43 topline data readout, Mar 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Annovis Bio, Inc. |
| Ticker | ANVS (NYSE) |
| SEC CIK | 1477845 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/anvs |

## Cash runway

Cash $2.8M as of 2026-09-30; quarterly burn $16.0M; about 0.5 months of runway at that rate (XBRL company facts, accession 0001104659-26-127105).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Aug 2022 | [Buntanetap trial start](https://sec-api.dev/pdufa/buntanetap) | ANVS |  | completed | "In August 2022, we initiated a Phase 3 clinical trial of buntanetap in 450 early PD patients, which were separated into three cohorts of 150 patients (the "Phase 3 PD Trial")." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1477845/000155837025003482/anvs-20241231x10k.htm)) |
| Feb 2023 | [Buntanetap trial start](https://sec-api.dev/pdufa/buntanetap) | ANVS |  | completed | "In February 2023, we initiated a Phase 2/3 AD Trial of buntanetap in 320 mild to moderate AD patients, which were separated into four cohorts of 80 patients." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1477845/000110465926027751/anvs-20251231x10k.htm)) |
| November 12, 2024 | [Annovis Bio, Inc. earnings report](https://sec-api.dev/companies/anvs/catalysts) | ANVS |  | completed | "Annovis Bio Reports Third Quarter Financial Results and Provides" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1477845/000110465924116086/tm2427939d1_ex99-1.htm)) |
| Feb 2025 | [ANVS-25001 trial start](https://sec-api.dev/pdufa/anvs-25001) | ANVS |  | completed | "During February of 2025, we initiated the FDA-cleared pivotal ANVS-25001 trial; a randomized, double-blind, placebo-controlled, multicenter Phase 3 trial in early AD patients." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1477845/000110465925110393/anvs-20250930x10q.htm)) |
| Feb 2025 | [Buntanetap trial start](https://sec-api.dev/pdufa/buntanetap) | ANVS |  | completed | "In February of 2025, we initiated the Phase 3 AD Trial of buntanetap in 760 early AD patients with 380 dosed and 380 placebo patients." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1477845/000110465926027751/anvs-20251231x10k.htm)) |
| May 9, 2025 | [Annovis Bio, Inc. earnings report](https://sec-api.dev/companies/anvs/catalysts) | ANVS |  | completed | "Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1477845/000110465925047871/tm2514854d1_ex99-1.htm)) |
| November 12, 2025 | [Annovis Bio, Inc. earnings report](https://sec-api.dev/companies/anvs/catalysts) | ANVS |  | completed | "Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1477845/000110465925110548/anvs-20251112xex99.htm)) |
| March 16, 2026 | [Annovis Bio, Inc. earnings report](https://sec-api.dev/companies/anvs/catalysts) | ANVS |  | completed | "Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1477845/000110465926028574/tm268976d1_ex99.htm)) |
| May 15, 2026 | [Annovis Bio, Inc. earnings report](https://sec-api.dev/companies/anvs/catalysts) | ANVS |  | completed | "Provides Corporate Updates and Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1477845/000110465926062451/tm2614822d1_ex99-1.htm)) |
| August 14, 2026 | [Buntanetap earnings report](https://sec-api.dev/pdufa/buntanetap) | ANVS |  | completed | "ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided business updates and reported financial results for the second quarter ended June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1477845/000110465926097091/tm2623272d1_ex99-1.htm)) |
| November 13, 2026 | [Annovis Bio, Inc. earnings report](https://sec-api.dev/companies/anvs/catalysts) | ANVS |  | completed | "Annovis Provides Corporate Updates and Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1477845/000110465926127094/tm2629728d1_ex99-1.htm)) |
| Mar 2027 | [TDP-43 topline data readout](https://sec-api.dev/pdufa/tdp-43) | ANVS |  | scheduled | ""Our Phase 3 AD clinical trial achieved significant enrollment growth, keeping us firmly on track to complete randomization of patients in summer 2026 and deliver first top-line results in early 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1477845/000110465926062451/tm2614822d1_ex99-1.htm)) |
| December 2027 | [Buntanetap/posiphen primary completion](https://sec-api.dev/pdufa/buntanetap-posiphen) | ANVS | Early Alzheimers Disease | scheduled | "NCT06709014 (A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Annovis Bio Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06709014)) |
| Dec 2027 to Mar 2028 | [Buntanetap/posiphen topline data readout](https://sec-api.dev/pdufa/buntanetap-posiphen) | ANVS | Early Alzheimers Disease | scheduled | "NCT06709014 (A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Annovis Bio Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06709014)) |
| September 2029 | [Buntanetap/posiphen primary completion](https://sec-api.dev/pdufa/buntanetap-posiphen) | ANVS | Parkinson's Disease (PD); Deep Brain Stimulation | scheduled | "NCT07284784 (A Study of Buntanetap in Participants With PD): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-09 (ESTIMATED); Lead Sponsor Annovis Bio Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07284784)) |
| Sep to Dec 2029 | [Buntanetap/posiphen topline data readout](https://sec-api.dev/pdufa/buntanetap-posiphen) | ANVS | Parkinson's Disease (PD); Deep Brain Stimulation | scheduled | "NCT07284784 (A Study of Buntanetap in Participants With PD): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-09 (ESTIMATED); Lead Sponsor Annovis Bio Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07284784)) |
| Feb to May 2030 | [Buntanetap/posiphen topline data readout](https://sec-api.dev/pdufa/buntanetap-posiphen) | ANVS | Alzheimer's Dementia (AD) | scheduled | "NCT07757204 (An Open-label Long-term Safety Study of Buntanetap in Participants With AD): Overall Status NOT_YET_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-02-21 (ESTIMATED); Lead Sponsor Annovis Bio Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07757204)) |
| February 2030 | [Buntanetap/posiphen primary completion](https://sec-api.dev/pdufa/buntanetap-posiphen) | ANVS | Alzheimer's Dementia (AD) | scheduled | "NCT07757204 (An Open-label Long-term Safety Study of Buntanetap in Participants With AD): Overall Status NOT_YET_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-02-21 (ESTIMATED); Lead Sponsor Annovis Bio Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07757204)) |

## Drugs

- [ANVS-25001](https://sec-api.dev/pdufa/anvs-25001): 
- [Buntanetap](https://sec-api.dev/pdufa/buntanetap): 
- [Buntanetap/posiphen](https://sec-api.dev/pdufa/buntanetap-posiphen): Early Alzheimers Disease, Alzheimer's Dementia (AD), Parkinson's Disease (PD)
- [TDP-43](https://sec-api.dev/pdufa/tdp-43): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/anvs/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ANVS catalysts: Annovis Bio, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/anvs/catalysts

```bibtex
@misc{secapidev_companies_anvs_catalysts_20261116,
  title        = {ANVS catalysts: Annovis Bio, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/anvs/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_anvs_catalysts_20261116","title":"ANVS catalysts: Annovis Bio, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/anvs/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
